Clinical trials: Intracerebral Haemorrhage (ICH)
- Condition Intracerebral Haemorrhage (ICH)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Cerebral Hemorrhage, Brain Hemorrhage
MIND: Artemis in the Removal of Intracerebral Hemorrhage
The primary objective of this multicenter randomized controlled study is to compare the safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Device to best medical management for the…
- Conditions
- Cerebral Hemorrhage, Brain Hemorrhage, Cerebral Parenchymal Hemorrhage, Intracerebral Hemorrhage
- Trial name
- NCT03342664
- Testing
- Artemis + Medical Management, Best Medical Management Alone (MM)
- Where
- 33 sites in United States, Austria and 2 more
- Volunteers
- 236 people
- Sponsor
- Penumbra Inc.
Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH)
Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).
This is a randomized, placebo-controlled, subject and investigator-blinded study to evaluate efficacy, safety and tolerability of BAF312 in participants with intracerebral hemorrhage (ICH)
- Trial name
- NCT03338998
- Testing
- BAF312 solution, BAF312 tablet
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Intracerebral Hemorrhage
Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage
This study employs a modified continual reassessment method (mCRM) design to estimate the maximum tolerated dose (MTD) of PF-05230907, defined as a target toxicity rate of 15% based on treatment emergent thromboembolic and/or…
- Trial name
- NCT02687191
- Testing
- PF-05230907
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 21 people
- Sponsor
- Pfizer